However, triple-negative breast cancer (TNBC), which accounts for about 10–20% of all breast cancers, has the poorest prognosis among the breast cancer subtypes because of the absence of therapeutic targets such as hormone receptors and human epidermal growth factor receptor 2 (HER2) [3,4,5]. This evidence concerns the gene ERBB2 and breast cancer.